Atrasentan

Atrasentan
Clinical data
ATC code
  • none
Identifiers
  • (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
ECHA InfoCard100.206.784 Edit this at Wikidata
Chemical and physical data
FormulaC29H38N2O6
Molar mass510.631 g·mol−1
3D model (JSmol)
  • O=C(O)[C@H]4[C@H](c1ccc(OC)cc1)N(CC(=O)N(CCCC)CCCC)C[C@@H]4c2ccc3OCOc3c2
  • InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1 checkY
  • Key:MOTJMGVDPWRKOC-QPVYNBJUSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer,[1] including non-small cell lung cancer.[2] It is also being investigated as a therapy for diabetic kidney disease.[3]

It is an endothelin receptor antagonist selective for subtype A (ETA). While other drugs of this type (sitaxentan, ambrisentan) exploit the vasoconstrictive properties of endothelin and are mainly used for the treatment of pulmonary arterial hypertension, atrasentan blocks endothelin induced cell proliferation.[citation needed]

  1. ^ "Atrasentan". NCI Dictionary of Cancer Terms. National Institute of Cancer. 2011-02-02.
  2. ^ Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, et al. (March 2008). "Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer". Clinical Cancer Research. 14 (5): 1464–9. doi:10.1158/1078-0432.CCR-07-1508. PMID 18316570.
  3. ^ "Atrasentan - Chinook Therapeutics". AdisInsight. Springer Nature Switzerland AG.